These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 30504306)
1. Molecular monitoring in CML: how deep? How often? How should it influence therapy? Shanmuganathan N; Hughes TP Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):168-176. PubMed ID: 30504306 [TBL] [Abstract][Full Text] [Related]
2. Molecular monitoring in CML: how deep? How often? How should it influence therapy? Shanmuganathan N; Hughes TP Blood; 2018 Nov; 132(20):2125-2133. PubMed ID: 30429156 [TBL] [Abstract][Full Text] [Related]
4. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review. Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712 [TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice. Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694 [No Abstract] [Full Text] [Related]
6. Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor. Baccarani M; Soverini S; De Benedittis C Am Soc Clin Oncol Educ Book; 2014; ():167-75. PubMed ID: 24857074 [TBL] [Abstract][Full Text] [Related]
7. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Shanmuganathan N; Pagani IS; Ross DM; Park S; Yong ASM; Braley JA; Altamura HK; Hiwase DK; Yeung DT; Kim DW; Branford S; Hughes TP Blood; 2021 Mar; 137(9):1196-1207. PubMed ID: 32871588 [TBL] [Abstract][Full Text] [Related]
8. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237 [TBL] [Abstract][Full Text] [Related]
9. Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia. Elsayed AG; Srivastava R; Jamil MO Curr Oncol Rep; 2017 Oct; 19(12):77. PubMed ID: 28988389 [TBL] [Abstract][Full Text] [Related]
10. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data. Zhu G; Yang Y; Wang H; Xie J; Hu J; Guo W; Zhang L; Liu Z; Chen X; Chang J; Xu J; Tan Y Ann Clin Lab Sci; 2020 Sep; 50(5):591-599. PubMed ID: 33067205 [TBL] [Abstract][Full Text] [Related]
11. Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Mahon FX; Etienne G Clin Cancer Res; 2014 Jan; 20(2):310-22. PubMed ID: 24166905 [TBL] [Abstract][Full Text] [Related]
12. Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia. Foroni L; Wilson G; Gerrard G; Mason J; Grimwade D; White HE; de Castro DG; Austin S; Awan A; Burt E; Clench T; Farruggia J; Hancock J; Irvine AE; Kizilors A; Langabeer S; Milner BJ; Nickless G; Schuh A; Sproul A; Wang L; Wickham C; Cross NC Br J Haematol; 2011 Apr; 153(2):179-90. PubMed ID: 21382019 [TBL] [Abstract][Full Text] [Related]
13. [The Evolution of the Treatment of Chronic Myelogenous Leukemia]. Onodera K; Fukuhara N Gan To Kagaku Ryoho; 2022 Oct; 49(10):1035-1039. PubMed ID: 36281590 [TBL] [Abstract][Full Text] [Related]
14. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758 [TBL] [Abstract][Full Text] [Related]
15. Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy. Boeckx N; Laer CV; Roover JD; Wilmsen B; Bruyninckx K; Pauwels S Acta Clin Belg; 2015 Aug; 70(4):237-43. PubMed ID: 26166681 [TBL] [Abstract][Full Text] [Related]
16. Chronic myeloid leukaemia: Biology and therapy. Wang Y; Liang ZJ; Gale RP; Liao HZ; Ma J; Gong TJ; Shao YQ; Liang Y Blood Rev; 2024 May; 65():101196. PubMed ID: 38604819 [TBL] [Abstract][Full Text] [Related]
17. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106 [TBL] [Abstract][Full Text] [Related]
18. Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia. Greiner G; Ratzinger F; Gurbisz M; Witzeneder N; Taghizadeh H; Mustafa SGK; Mitterbauer-Hohendanner G; Esterbauer H; Mannhalter C; Sperr WR; Valent P; Hoermann G Clin Chem Lab Med; 2020 Jul; 58(8):1214-1222. PubMed ID: 32084002 [TBL] [Abstract][Full Text] [Related]